Autopsy report · NCT00551759

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

“The study used a two-stage design. After stage one, the study was terminated due to excess toxicity.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 11 months before it started.
• Ran for about 5 years 4 months before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 0 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Eastern Cooperative Oncology Group

Sponsor type

University, hospital or other

Conditions

Esophageal Cancer

Interventions

5-Fluorouracil; Oxaliplatin; Cetuximab; Docetaxel; Surgery; Radiotherapy

Participants

22

Sites

109

Countries

United States

Trials that died the same way

• Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
  “Study terminated due to toxicity” (77% match in meaning)
• Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
  “The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.” (73% match in meaning)
• A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)
  “This study was terminated due to limited efficacy and not due to safety reasons” (73% match in meaning)
• Phase II Study of TAEST16001 in Soft Tissue Sarcoma
  “The study was terminated due to initiation of a new clinical trial with an updated study design.” (71% match in meaning)
• A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
  “Study was prematurely discontinued due to unacceptable toxicity.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.